KRX 168

Drug Profile

KRX 168

Alternative Names: KRX-168

Latest Information Update: 03 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Keryx Biopharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Post-surgical adhesions

Most Recent Events

  • 03 Dec 2006 Discontinued - Preclinical for Post-surgical adhesions in Israel
  • 05 Oct 2000 New profile
  • 05 Oct 2000 Preclinical development for Post-surgical adhesions in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top